The clinical study performed by TransPharma Medical, measured the transdermal drug delivery of insulin to healthy adult volunteers using the ViaDerm System.
 

Delivery of Insulin in Humans

Glucose Infusion Rate (Mean + SD)

The study, employing a glucose clamping technique, was carried out in two parts: In the first part, an 8.5 cm² printed patch containing 150 IU of human insulin was applied on ViaDerm treated skin area of 5 healthy subjects. In the second part, a 10 IU dose of human insulin was injected subcutaneously to the same healthy subjects.

The results of the study clearly demonstrate that therapeutic amounts of insulin can be delivered across the human skin using the ViaDerm system; 10 IU of insulin were delivered from an 8.5 cm² printed patch. By comparing bioavailability and biopotency values TransPharma Medical has confirmed that the transdermally delivered insulin maintained full bioactivity. Dermal safety evaluation resulted in slight irritation which resolved within 24 hours following patch removal.